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Background and purpose — The safety aspects of bilateral simul-
taneous total knee arthroplasty (BSTKA) are still debated. In this 
retrospective single-center study, we investigated early morbidity 
and mortality following BSTKA in a modern fast-track setting. 
We also identified risk factors for re-admission within 90 days and 
for a length of stay (LOS) of more than 5 days.
Patients and methods — 284 patients were selected to receive 
BSTKA at our institution from 2008 through 2014 in a well-
described, standardized fast-track setup (Husted 2012 a, b). All 
re-admissions within 90 days were identified and mortality rates 
and time until death were recorded. Transfusion rates and num-
bers of transfusions were also recorded. Logistic regression analy-
sis was used to identify risk factors for re-admission within 90 
days, and also for a LOS of more than 5 days.
Results — 90-day mortality was 0%. 10% of the patients were 
re-admitted within 90 days. Median time to re-admission was 
18 (3–75) days. 153 patients (54%) received postoperative blood 
transfusions. An ASA score of 3 was identified as an independent 
risk factor for re-admission within 90 days (OR = 5, 95% CI: 
1.3–19) and for LOS of > 5 days (OR = 6, 95% CI: 1.6–21). Higher 
BMI was a weak risk factor for re-admission within 90 days.
Interpretation — BSTKA in selected patients without cardio-
pulmonary disease in a fast-track setting appears to be safe with 
respect to early postoperative morbidity and mortality. Surgeons 
should be aware that patients with an ASA score of 3 have an 
increased risk of re-admission and a prolonged length of stay, 
while patients with higher BMI have an increased risk of re-
admission following BSTKA.

Fast-track knee arthroplasty is a cost-efficient and safe treat-
ment method for osteoarthritis of the knee, with excellent 
patient satisfaction, early functional recovery, and low post-
operative morbidity and mortality (Kehlet 2013). Close to 
one-third of patients scheduled to undergo primary TKA pres-
ent with bilateral symptoms (Metcalfe et al. 2012). In these 
cases, the surgeon can choose to either perform a staged pro-
cedure or a simultaneous bilateral procedure, depending on 
comorbidities, the preference of the patient, and so on. The 
proposed benefits of bilateral simultaneous TKA (BSTKA), 
including reduced total financial costs and shorter total conva-
lescence period (Odum et al. 2013, Lin et al. 2014), have led 
to an increased number of simultaneous procedures in recent 
decades (Hooper et al. 2009, Memtsoudis et al. 2013, Poult-
sides et al. 2014, Lindberg-Larsen et al. 2015). However, the 
safety aspects of BSTKA are still debated, as several studies 
have shown a higher risk of postoperative complications and 
even higher postoperative mortality after simultaneous proce-
dures than after staged procedures (Restrepo et al. 2007, Ste-
fánsdóttir et al. 2008, Hu et al. 2011, Bolognesi et al. 2013). 
On the other hand, other authors have reported that BSTKA is 
safe without any increase in postoperative morbidity and mor-
tality (Hooper et al. 2009, Bini et al. 2014, Lindberg-Larsen 
et al. 2015).
Comparison of studies on BSTKA is complicated by the 
use of different inclusion criteria, different patient popula-
tions, and different perioperative protocols. Few studies have 
investigated mortality and morbidity following BSTKA in a 
fast-track setting (Husted et al. 2011, Hart et al. 2015). Further 
studies are needed to evaluate the safety aspects of simultane-
ous procedures performed in a modern fast-track setup, with 
surgery performed without drains or tourniquet, same-day 
mobilization, and a short length of stay (LOS).
In this retrospective single-center study, we investigated 
early morbidity and mortality following BSTKA in a modern 
fast-track setting. We also identified risk factors for re-admis-
sion within 90 days and for a LOS of more than 5 days.
Acta Orthopaedica 2016; 87 (3): 286–290286 
 Patients and methods
284 patients were selected to receive BSTKA at our institu-
tion from 2008 through 2014 in a well-described, standard-
ized fast-track setup (Husted 2012). All patients presented 
with painful bilateral knee osteoarthritis, had no known car-
diopulmonary comorbidity, and were operated by a consultant 
specialized in joint replacement surgery. Minimum follow-up 
was 1 years (range: 1–7.5). Median age was 65 (33–86) years, 
53% of the patients (150/284) were female, and mean BMI 
was 30 (19–50). 26% of the patients had an ASA score of 1, 
68%  had an ASA score of 2, and 6% had an ASA score of 3. 
All patients received a total knee prostheses—AGC (Biomet), 
Vanguard (Biomet), NexGen (Zimmer), or PFC Sigma (DePuy 
Synthes)—using a standard medial parapatellar approach with-
out the use of a tourniquet. The left knee was operated first 
and surgery was performed sequentially. Cutting guides were 
applied externally on the tibia and intramedullary on the femur. 
The standard surgical protocol included spinal analgesia, stan-
dardized fluid management, use of preoperative intravenous 
tranexamic acid (TXA), plugging of the femoral medullary 
canal, absence of drains, application of local infiltration anal-
gesia (LIA), and use of postoperative compression bandaging. 
The multimodal opioid-sparing analgesic regime included use 
of non-steroidal anti-inflammatory drugs, paracetamol, local 
infiltration anesthesia (LIA applied at the end of surgery only, 
no catheters), and opioids only upon request.  
The patients were transferred from the postoperative recov-
ery unit to the patient ward after a few hours, where immedi-
ate mobilization was attempted, allowing full-weight bearing. 
Physiotherapy was started on the day of surgery and continued 
until discharge.  Rivaroxaban (Bayer, Denmark) was used as 
oral thromboprophylaxis, starting 6–8 hours postoperatively 
and continuing on a daily basis until discharge. Mechanical 
thromboprophylaxis and extended oral thromboprophylaxis 
were not used. A transfusion protocol was applied with blood 
transfusions triggered by a 25% decrease in postoperative 
hemoglobin compared to preoperative values, combined with 
clinical signs of anemia such as dizziness, shortness of breath, 
and/or pallor. Patients were discharged when the functional 
discharge criteria were met, which included being able to 
undertake independent personal care, being able to walk 70 m 
with or without crutches, being able to get in and out of bed, 
and being able to get up independently from a chair or toilet. 
LOS was recorded and counted in whole days as the number 
of postoperative nights in the hospital. All re-admissions 
within 90 days were identified and the reason for re-admission 
recorded. Mortality rates and time until death were recorded. 
Transfusion rates and number of transfusions were also 
recorded. 
Statistics
Comparisons were performed using 2-sample t-test for nor-
mally distributed data and a two-sample Wilcoxon rank-sum 
test for data that were not normally distributed. Proportions 
were compared using the Pearson chi-squared test. Logistic 
regression analysis was used to identify risk factors for re-
admission within 90 days and for LOS of more than 5 days, 
while adjusting for age, sex, ASA score, and BMI.
Any p-value less than 0.05 was considered statistically sig-
nificant. All analyses were performed using SPSS statistics 
software version 21.
Results
90-day mortality was 0%. 10% of patients were re-admitted 
within 90 days, with 8% being re-admitted within 30 days. 
Median time to re-admission was 18 (3–75) days. Surgical site 
infection treated either with antibiotics alone (n = 2) or with 
revision (n = 6) was the most common reason for re-admission 
(Table 1). The proportion of re-admitted patients was not sig-
nificantly different in between years during the study period (p 
= 0.9). Median LOS for all patients was 3 (2–30) days. 14% of 
all patients had a LOS of more than 5 days (data not shown). 
54% of patients received blood transfusions postoperatively 
and 21% received more than 2 units of blood.
Patients with an ASA score of 3 had an OR of 4.9 (95% 
CI: 1.3–19) for re-admission within 90 days (Table 2) and an 
OR of 5.8 (95% CI: 1.6–21) for a LOS of more than 5 days 
(Table 3). Higher BMI was associated with an increased risk 
of re-admission within 90 days (OR = 1.1, 95% CI: 1.01–1.2) 
(Table 2).
Table 1. Reasons for 29 re-admissions within 90 days of BSTKA
Reason for re-admission n 
Suspicion of DVT a 2 
Suspicion of infection b 6 
Cardiac c 4 
Thromboembolic d 2 
Infection e 8 
Other f 7 
Total 29 
a Suspicion of deep-vein thrombosis (DVT), refuted by ultrasound.
b Suspicion of infection, refuted by clinical examination and blood 
sampling.
c Patients with chest pains. Cardiac ischemia refuted by blood 
sampling. 1 patient with atrial fibrillation (medically treated).
d 2 patients with DVT confirmed by ultrasound (medically treated).
e 6 patients with clinically confirmed infection (treated with surgi-
cal revision). 2 patients with superficial site infection (treated 
with antibiotics).  
f 2 patients admitted for further mobilization, 1 patient admitted 
due to wound oozing without suspicion of infection, 1 patient 
with urinary tract infection, 2 patients with gastric symptoms, 
and 1 patient with dehydration.
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Discussion 
The safety of BSTKA regarding mortality and morbidity is 
debatable, as several studies have shown higher mortality fol-
lowing simultaneous bilateral procedures than after staged 
bilateral procedures (Parvizi et al. 2001, Stefánsdóttir et al. 
2008) while others have failed to show any differences (Bull-
ock et al. 2003, Lindberg-Larsen et al. 2015). The 3 most 
recent meta-analyses comparing morbidity and mortality fol-
lowing BSTKA (Restrepo et al. 2007, Fu et al. 2013, Hussain 
et al. 2013) all concluded that BSTKA carries a higher risk of 
postoperative mortality. Conclusions on postoperative compli-
cations are less sure, as meta-analyses by both Hussein et al. 
(2007) and Fu et al. (2001) found similar rates of thrombo-
embolic and cardiac complications and also infections, while 
Restrepo et al. (2007) found a higher risk of cardiac and pul-
monary complications following BSTKA than after staged 
procedures. 
Our finding of a 90-day mortality of 0% following BSTKA 
in a standardized fast-track setting is encouraging, and it is 
similar to previous reports on early postoperative mortality for 
bilateral procedures in a fast-track setting, as both Lindberg et 
al. (2015) and Husted et al. (2011) also reported 0% 90-day 
mortality following BSTKA, while Poultside et al. (2014) 
found a 30-day mortality rate of 0.04% in a cohort of 4,825 
BSTKA patients. It is important to point out that the study by 
Husted et al. (2011) included patients who were operated in 
2008 (n = 32), thus having a small overlap with the present 
study. The low mortality rates stand in contrast to the 0.5% 
30-day mortality following BSTKA reported by Parvizi et al. 
(2001), the 0.15% in-hospital mortality reported by Odum 
et al. (2014), and the 0.3% in-hospital mortality reported by 
Memtsoudis et al. (2009). One possible explanation for the 
zero mortality found in our study was the fast-track setup 
itself, which may have reduced postoperative morbidity and 
mortality for both total knee arthroplasty patients and total 
hip arthroplasty patients (Husted et al. 2010a,b, Kehlet 2013, 
Lindberg-Larsen et al. 2013, 2015). 
The 10% re-admission rate within 90 days and the 8% re-
admission rate within 30 days found in the present study is 
comparable to the 7% re-admission rate within 30 days fol-
lowing simultaneous bilateral procedures reported by Lind-
berg et al. (2015) in a nationwide study, and to the 7% re-
admission rate within 30 days following staged bilateral 
procedures reported by Kheir et al. (2014). Hart et al. (2015) 
have reported lower 30-day re-admission rates following 
BSTKA—4% as compared to the 8% value found in the pres-
ent study, but this might be explained by varying definitions 
of re-admission between studies, and the possibility of com-
plete follow-up (Husted 2012). A 90-day re-admission rate of 
9% following unilateral TKA in a modern fast-track setting 
has been reported in a recent nationwide study (Jørgensen 
and Kehlet 2013). This supports the safety aspect of BSTKA, 
which in our hands has similar re-admission rates to those of 
unilateral TKA, as the patients receiving 2 unilateral TKAs 
would have a higher cumulative re-admission rate over time. 
Our finding that postoperative infection is the most common 
cause of re-admission is also in agreement with the findings 
of both Kheir et al. (2014) and Lindberg et al. (2015). It is 
interesting that there were no re-admissions due to pulmonary 
embolism (PE) and only 2 re-admissions (0.7%) due to deep-
vein thrombosis (DVT) in our patient cohort, which can be 
compared with the DVT rate of 0.9% and the PE rate of 1% 
within 60 days reported by Meehan et al. (2011) and the DVT 
and PE rates of 1% and 0.8%, respectively, following BSTKA 
reported by Memtsoudis et al. (2009) in nationwide studies. 
The 0.7% (2/284) risk of re-admission within 90 days due to 
thromboembolic events found in our study is lower than the 
2% 90-day risk of re-admission due to thromboembolic events 
reported in fast-track departments in a nationwide study 
(Glassou et al. 2014). Less comorbidity in patients undergo-
ing BSTKA is the most likely explanation for this difference. 
The median LOS of 3 days found in the present study  is 
similar to LOS figures in previous studies on fast-track total 
knee arthroplasty (Husted et al. 2011, Jørgensen and Kehlet 
2013). This shows that almost all the patients selected can ful-
fill the functional discharge criteria within just a few days after 
this major surgical procedure.
We found a high transfusion rate, as more than 50% of 
patients required postoperative blood transfusions. This find-
ing is not unexpected, as several previous studies have found 
high transfusion rates following simultaneous bilateral pro-
cedures: 95% was found by Stubbs et al. (2005), 55% was 
Table 2. Odds ratio for re-admission within 90 days of BSTKA
Parameter OR (95% CI) p-value
Age, years a 1.1   (0.99–1.1) 0.09
Female sex 0.93 (0.40–2.2) 0.9
ASA score 2 0.70 (0.25–2.0) 0.5
ASA score 3 4.9   (1.3–19) 0.02
BMI b 1.1   (1.01–1.2) 0.04
 
a Age included as a continuous variable.
b BMI included as a continuous variable.
Table 3. Odds ratio for a length of stay (LOS) of more than 5 days 
following primary BSTKA
Parameter OR (95% CI) p-value
Age, years a 1.0 (0.99–1.1) 0.1
Female sex 1.2 (0.59–2.5) 0.6
ASA score 2 1.2 (0.48–3.1) 0.7
ASA score 3 5.8 (1.6–21) 0.008
BMI b 1.0 (0.95–1.1) 0.7
 
a Age included as a continuous variable.
b BMI included as a continuous variable.
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found by Jenny et al. (2013), and 45% was found by Husted 
et al. (2011). A recent study performed by Kim et al. (2014) 
did, however, show a much lower transfusion rate of 7% for 
BSTKA when TXA was administered in multiple doses, indi-
cating the possibility of reducing transfusions more than the 
blood-saving protocol currently being used at our institution. 
However, we do not know what role the high transfusion rate 
reported in our study plays regarding the complication rate 
and postoperative outcomes, as blood transfusion has been 
linked to infections (Friedman et al. 2014). Further investiga-
tion is therefore required, focusing on intraoperative and total 
blood loss following BSTKA in order to optimize conserva-
tion of blood. 
Finally, we found patients with an ASA score of 3 to have an 
increased risk of re-admission within 90 days and an increased 
risk of having a LOS of more than 5 days. This is hardly sur-
prising, as similar results have been reported for unilateral 
procedures (Husted et al. 2010a, Husted 2012). It is, however, 
surprising that 17 patients (6%) with an ASA score of 3 were 
offered—and underwent—BSTKA in our study. This con-
trasts with a recent consensus paper, which stated that only 
patients with few comorbidities should be offered BSTKA 
(Memtsoudis et al. 2013). This is supported by our finding 
that 7 of the 17 patients with an ASA score of 3 were re-
admitted within 90 days. However, it is not possible to specu-
late whether these re-admissions could have been avoided if 
patients with an ASA score of 3 had undergone a staged bilat-
eral procedure instead. 
Obesity is a well-known risk factor for complications fol-
lowing TKA, including increased risk of infections, of pro-
longed wound drainage, and of thromboembolic complica-
tions (Belmont et al. 2014, Thornqvist et al. 2014, Alvi et al. 
2015, Si et al. 2015). Thus, our finding that higher BMI was 
associated with an increased risk, albeit small, of re-admission 
within 90 days is in agreement with the previous literature 
(Fabi et al. 2011). 
The main limitation of our study was the retrospective 
design without any control group. The retrospective data col-
lection allowed possible inaccuracies regarding the param-
eters collected, and the lack of a control group did not allow 
comparisons and therefore limited our conclusions. The opti-
mal design for evaluating the safety and efficiency of BSTKA 
would be a randomized controlled study comparing staged and 
simultaneous procedures. However, such a setup would have a 
challenging patient inclusion, which is one of the reasons why 
such trials have not been performed to date (Memtsoudis et al. 
2013). Addition of a control group of staged bilateral proce-
dures, as previously done by Husted et al. (2011), would allow 
comparison of simultaneous with staged procedures. How-
ever, such case-control studies with matching of 1 or multiple 
parameters would still permit selection bias, as the surgeon’s 
choice for performing a staged rather than a simultaneous 
procedure and vice versa would be unaccounted for. We have 
therefore presented strictly descriptive data showing safety 
aspects with respect to mortality and re-admission following 
BSTKA in selected patients. Secondly, we only investigated 
re-admissions and mortality without investigating patient-
reported outcomes. However, we have already reported 
patient satisfaction in another cohort of BSTKA patients 
from our study population (Husted et al. 2011). Thirdly, ASA 
score was the only parameter that we included to account for 
patient comorbidities, and it is known to be associated with 
great interobserver variability (Mak et al. 2002). Finally, the 
follow-up for re-admission and mortality was limited to 90 
days, which does not allow us to make any conclusions on late 
surgical complications such as aseptic loosening. However, 
evaluation of late surgical complications is outside the scope 
of the current study, and we believe that death more than 90 
days after the procedure is unlikely to have been associated 
with the procedure itself. 
In conclusion, BSTKA in selected patients without cardio-
pulmonary disease in a fast-track setting appears to be safe 
regarding early postoperative morbidity and mortality. Sur-
geons should be aware that patients with an ASA score of 3 
have an increased risk of re-admission and prolonged length 
of stay, while patients with higher BMI have an increased risk 
of re-admission after BSTKA. 
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